UroGen Pharma Files 2024 Annual Report Amendment
Ticker: URGN · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceutical
TL;DR
UroGen Pharma filed its amended 2024 10-K. Check for updates.
AI Summary
UroGen Pharma Ltd. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 30, 2025, provides updated information for the company, which is incorporated in Israel and has its principal executive offices in Princeton, NJ.
Why It Matters
This amendment provides updated financial and operational information for UroGen Pharma Ltd. for the fiscal year 2024, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is an amendment to a standard annual report, indicating it's an update rather than a new event.
Key Numbers
- 001-38079 — Commission file number (Identifies the company's SEC filings)
- 98-1460746 — I.R.S. Employer Identification Number (Tax identification for the company)
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- 2024-12-31 (date) — Fiscal year end
- 2025-04-30 (date) — Filing date
- Israel (location) — Jurisdiction of incorporation
- Princeton, NJ (location) — Principal executive offices
FAQ
What specific changes or updates are detailed in this 10-K/A amendment?
The filing is an amendment to the annual report for the fiscal year ended December 31, 2024, but the specific details of the amendments are not provided in the header information.
When was the original 10-K filed for the fiscal year ended December 31, 2024?
The filing header indicates this is an amendment (10-K/A) to the report for the fiscal year ended December 31, 2024, filed as of April 30, 2025. The original filing date is not explicitly stated but would precede this amendment.
What is UroGen Pharma Ltd.'s primary business sector?
UroGen Pharma Ltd. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where are UroGen Pharma Ltd.'s principal executive offices located?
The principal executive offices are located at 400 Alexander Park, Princeton, NJ 08540.
What is the significance of the filing date of April 30, 2025?
The filing date of April 30, 2025, indicates when this amendment to the annual report was submitted to the SEC.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding UroGen Pharma Ltd. (URGN).